Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

5.14
-0.4200-7.55%
Post-market: 5.170.0300+0.58%17:49 EDT
Volume:14.82M
Turnover:78.08M
Market Cap:1.80B
PE:-11.72
High:5.66
Open:5.66
Low:5.03
Close:5.56
52wk High:9.75
52wk Low:3.36
Shares:351.12M
Float Shares:264.00M
Volume Ratio:3.80
T/O Rate:5.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:7.11
PE(LYR):-8.57

Loading ...

Nuvation Bio Shares up 1% After Citigroup Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Sep 30

Nuvation Bio Gains After Citi Initiates with "buy"

Reuters
·
Sep 30

Nuvation Bio Initiated at Buy by Citigroup

Dow Jones
·
Sep 30

Nuvation Bio Inc. : Citigroup Initiates Coverage with Buy Rating; Target Price $12

THOMSON REUTERS
·
Sep 30

Nuvation Bio initiated with a Buy at Citi

TIPRANKS
·
Sep 30

Citigroup Initiates Nuvation Bio at Buy With $12 Price Target

MT Newswires Live
·
Sep 30

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

TIPRANKS
·
Sep 17

Nuvation Bio Wins FDA Nod to Update Ibtrozi Label with 49.7-Month Response Duration in TRUST-I Study

Reuters
·
Sep 17

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) with Updated Duration of Response in Tki-NaÏVe Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 17

Nuvation Bio - no Changes to Ibtrozi Safety Labeling; no New Safety Signals Identified

THOMSON REUTERS
·
Sep 17

Nuvation Bio Price Target Maintained with a $11.00/Share by Wedbush

Dow Jones
·
Sep 16

Nuvation Bio CEO, CFO to Present at Citi Biopharma Conference Fireside Chat

Reuters
·
Sep 03

Nuvation Bio CSO Gary Hattersley Disposes of Class a Common Shares Worth $709,240

Reuters
·
Aug 22

Cantor Fitzgerald Initiates Nuvation Bio at Overweight

MT Newswires Live
·
Aug 21

Nuvation Bio Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Aug 21

Nuvation Bio initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Aug 21

Nuvation Bio Wins FDA Fast-Track Status for Safusidenib in IDH1-Mutant Glioma

Reuters
·
Aug 20

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of Idh1-Mutant Glioma

THOMSON REUTERS
·
Aug 20

Nuvation Bio Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $13

THOMSON REUTERS
·
Aug 18

Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership

Simply Wall St.
·
Aug 11